NCT01953640View on ClinicalTrials.gov

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

Active, not recruitingOBSERVATIONAL
Enrollment

92

Participants

Timeline

Start Date

May 30, 2013

Primary Completion Date

December 3, 2015

Study Completion Date

December 15, 2026

Conditions
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaProstate AdenocarcinomaRecurrent Prostate Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (3)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER